Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.17
NYSE:ALR's Cash to Debt is ranked lower than
88% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.88 vs. NYSE:ALR: 0.17 )
Ranked among companies with meaningful Cash to Debt only.
NYSE:ALR' s Cash to Debt Range Over the Past 10 Years
Min: 0.08  Med: 0.14 Max: 1.88
Current: 0.17
0.08
1.88
Equity to Asset 0.35
NYSE:ALR's Equity to Asset is ranked lower than
78% of the 186 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.58 vs. NYSE:ALR: 0.35 )
Ranked among companies with meaningful Equity to Asset only.
NYSE:ALR' s Equity to Asset Range Over the Past 10 Years
Min: -0.09  Med: 0.38 Max: 0.77
Current: 0.35
-0.09
0.77
Interest Coverage 0.35
NYSE:ALR's Interest Coverage is ranked lower than
98% of the 127 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 83.10 vs. NYSE:ALR: 0.35 )
Ranked among companies with meaningful Interest Coverage only.
NYSE:ALR' s Interest Coverage Range Over the Past 10 Years
Min: 0.24  Med: 0.48 Max: 1.37
Current: 0.35
0.24
1.37
F-Score: 4
Z-Score: 0.85
M-Score: -2.79
WACC vs ROIC
2.39%
0.97%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 2.87
NYSE:ALR's Operating margin (%) is ranked higher than
52% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.48 vs. NYSE:ALR: 2.87 )
Ranked among companies with meaningful Operating margin (%) only.
NYSE:ALR' s Operating margin (%) Range Over the Past 10 Years
Min: -44.13  Med: 2.37 Max: 7.6
Current: 2.87
-44.13
7.6
Net-margin (%) -2.81
NYSE:ALR's Net-margin (%) is ranked lower than
51% of the 199 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.51 vs. NYSE:ALR: -2.81 )
Ranked among companies with meaningful Net-margin (%) only.
NYSE:ALR' s Net-margin (%) Range Over the Past 10 Years
Min: -47.2  Med: -2.87 Max: 1.75
Current: -2.81
-47.2
1.75
ROE (%) -4.29
NYSE:ALR's ROE (%) is ranked higher than
51% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.35 vs. NYSE:ALR: -4.29 )
Ranked among companies with meaningful ROE (%) only.
NYSE:ALR' s ROE (%) Range Over the Past 10 Years
Min: -34.13  Med: -4.43 Max: 0.32
Current: -4.29
-34.13
0.32
ROA (%) -1.10
NYSE:ALR's ROA (%) is ranked higher than
54% of the 212 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -6.30 vs. NYSE:ALR: -1.10 )
Ranked among companies with meaningful ROA (%) only.
NYSE:ALR' s ROA (%) Range Over the Past 10 Years
Min: -15.33  Med: -1.47 Max: 0.52
Current: -1.1
-15.33
0.52
ROC (Joel Greenblatt) (%) 4.54
NYSE:ALR's ROC (Joel Greenblatt) (%) is ranked higher than
56% of the 211 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -10.22 vs. NYSE:ALR: 4.54 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
NYSE:ALR' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -169.25  Med: 9.33 Max: 22.61
Current: 4.54
-169.25
22.61
Revenue Growth (3Y)(%) 2.80
NYSE:ALR's Revenue Growth (3Y)(%) is ranked lower than
57% of the 141 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.80 vs. NYSE:ALR: 2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
NYSE:ALR' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -8.6  Med: 12.75 Max: 36.1
Current: 2.8
-8.6
36.1
EBITDA Growth (3Y)(%) -0.60
NYSE:ALR's EBITDA Growth (3Y)(%) is ranked higher than
50% of the 123 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.80 vs. NYSE:ALR: -0.60 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
NYSE:ALR' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -9.3  Med: 8.4 Max: 102.9
Current: -0.6
-9.3
102.9
EPS Growth (3Y)(%) 13.70
NYSE:ALR's EPS Growth (3Y)(%) is ranked higher than
76% of the 117 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.10 vs. NYSE:ALR: 13.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
NYSE:ALR' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -57.2  Med: 2.2 Max: 76.1
Current: 13.7
-57.2
76.1
» NYSE:ALR's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-11-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q3 2015

ALR Guru Trades in Q3 2015

Mario Gabelli 233,430 sh (+6.88%)
Private Capital 941,823 sh (+1.59%)
Keeley Asset Management Corp 974,047 sh (-6.81%)
Diamond Hill Capital 2,058,095 sh (-8.26%)
Steven Cohen 557,400 sh (-19.28%)
Jim Simons 1,113,424 sh (-20.17%)
Manning & Napier Advisors, Inc 531,294 sh (-22.12%)
» More
Q4 2015

ALR Guru Trades in Q4 2015

Manning & Napier Advisors, Inc 1,481,660 sh (+178.88%)
Diamond Hill Capital 2,306,319 sh (+12.06%)
Mario Gabelli 235,430 sh (+0.86%)
Keeley Asset Management Corp 964,189 sh (-1.01%)
Private Capital 930,548 sh (-1.20%)
Jim Simons 878,424 sh (-21.11%)
Steven Cohen 324,000 sh (-41.87%)
» More
Q1 2016

ALR Guru Trades in Q1 2016

George Soros 42,800 sh (New)
Jeremy Grantham 736,344 sh (New)
Mario Gabelli 494,105 sh (+109.87%)
Private Capital 933,725 sh (+0.34%)
Steven Cohen Sold Out
Manning & Napier Advisors, Inc Sold Out
Keeley Asset Management Corp 713,314 sh (-26.02%)
Jim Simons 506,724 sh (-42.31%)
Diamond Hill Capital 1,052,078 sh (-54.38%)
» More
Q2 2016

ALR Guru Trades in Q2 2016

Leucadia National 79,457 sh (New)
First Eagle Investment 766,566 sh (New)
Jeremy Grantham 1,520,100 sh (+106.44%)
Mario Gabelli 528,225 sh (+6.91%)
Diamond Hill Capital 1,074,665 sh (+2.15%)
George Soros Sold Out
Private Capital 849,998 sh (-8.97%)
Jim Simons 408,824 sh (-19.32%)
Keeley Asset Management Corp 520,100 sh (-27.09%)
» More
» Details

Insider Trades

Latest Guru Trades with ALR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Preferred stocks of Alere Inc

SymbolPriceYieldDescription
ALRPRB343.033.50

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research
Compare:NAS:VWR, NAS:PRXL, NAS:CPHD, NAS:BRKR, NYSE:CRL, NAS:PRAH, NAS:ICLR, OTCPK:CZMWY, NYSE:BIO.B, NAS:INCR, NAS:NEOG, NAS:EXAS, NAS:MYGN, OTCPK:BMXMF, NYSE:PKI, NAS:AXDX, NAS:QGEN, NAS:KANG, NAS:ABAX, NAS:ALOG » details
Traded in other countries:IM5.Germany,
Alere Inc enables individuals to take charge of improving their health and quality of life at home. The Company operates in three segments; professional diagnostics, health information solutions and consumer diagnostics.

Alere Inc formerly known as Inverness Medical Innovations, Inc. is a Delaware corporation incorporated on August 25,1992, which was formed to acquire the women's health, nutritional supplements and professional diagnostics businesses of its predecessor, Inverness Medical Technology, Inc., through a split-off and merger transaction, which occurred in November 2001. The Company enables individuals to take control of their health at home, under the supervision of their healthcare providers, by connecting diagnostics in the hands of patients to their healthcare providers. The Company is a provider of point-of-care diagnostics and services; and has developed a commercial presence in infectious disease, toxicology, cardiology and diabetes. Its products and services help healthcare practitioners make earlier, more effective treatment decisions and improve outcomes for individuals living with chronic disease. Its portfolio also includes a broad array of health information solutions that increase access to critical health data, provide clinical decision support and facilitate more comprehensive performance reporting and analysis. The Company's operating segments are professional diagnostics, health information solutions and consumer diagnostics. Professional Diagnostics solutions allow patients and their healthcare providers to work together to manage patients' chronic conditions over the continuum of care, from the hospital to home. It is generally designed to assist medical professionals in both preventative and interventional medicine, and include testing and monitoring performed in hospitals, laboratories and doctors' offices and, increasingly, patient self-testing, which defined as testing or monitoring performed at home under the supervision of a medical professional. Its products provide for qualitative or quantitative analysis of patient samples for evidence of a specific medical condition, disease state or toxicological state or to measure response to therapy. In professional diagnostics, Company focus on point-of-care, rapid diagnostic testing and the developing patient self-testing and patient self-management markets where it can directly and immediately improve patient health outcomes. Its products include point-of-care and laboratory tests within the following areas; Infectious Disease, Toxicology, Cardiology, Diabetes, Oncology, Women's Health and Connected Device Technologies. Its health information solutions are designed to provide physicians with actionable data that allows them to make more effective decisions in real time, deliver quality care, and put the individuals treat on a pathway to health. It offers a variety of software-based analytics, clinical decision-support tools, and accountable care programs that enable healthcare providers to initiate earlier interventions, personalize treatment plans, lower costs by reducing hospital readmissions, and measure improvements in outcomes at both a patient and population le

Ratios

vs
industry
vs
history
Forward P/E 17.86
ALR's Forward P/E is ranked higher than
76% of the 42 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 21.74 vs. ALR: 17.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
Price/Owner Earnings (ttm) 65.36
ALR's Price/Owner Earnings (ttm) is ranked lower than
83% of the 58 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.42 vs. ALR: 65.36 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ALR' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 9.34  Med: 20.32 Max: 2417.22
Current: 65.36
9.34
2417.22
P/B 2.67
ALR's P/B is ranked higher than
64% of the 179 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.47 vs. ALR: 2.67 )
Ranked among companies with meaningful P/B only.
ALR' s P/B Range Over the Past 10 Years
Min: 0.42  Med: 1.67 Max: 3.21
Current: 2.67
0.42
3.21
P/S 1.55
ALR's P/S is ranked higher than
76% of the 181 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.27 vs. ALR: 1.55 )
Ranked among companies with meaningful P/S only.
ALR' s P/S Range Over the Past 10 Years
Min: 0.52  Med: 1.43 Max: 3.97
Current: 1.55
0.52
3.97
PFCF 19.37
ALR's PFCF is ranked higher than
64% of the 61 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 23.45 vs. ALR: 19.37 )
Ranked among companies with meaningful PFCF only.
ALR' s PFCF Range Over the Past 10 Years
Min: 8.53  Med: 19.05 Max: 112.72
Current: 19.37
8.53
112.72
POCF 13.88
ALR's POCF is ranked higher than
64% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 18.96 vs. ALR: 13.88 )
Ranked among companies with meaningful POCF only.
ALR' s POCF Range Over the Past 10 Years
Min: 4.63  Med: 11.81 Max: 124.49
Current: 13.88
4.63
124.49
EV-to-EBIT 139.05
ALR's EV-to-EBIT is ranked lower than
97% of the 94 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 22.20 vs. ALR: 139.05 )
Ranked among companies with meaningful EV-to-EBIT only.
ALR' s EV-to-EBIT Range Over the Past 10 Years
Min: -676  Med: 52.55 Max: 683.2
Current: 139.05
-676
683.2
EV-to-EBITDA 19.29
ALR's EV-to-EBITDA is ranked lower than
59% of the 105 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 16.73 vs. ALR: 19.29 )
Ranked among companies with meaningful EV-to-EBITDA only.
ALR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -173.6  Med: 12.65 Max: 87.3
Current: 19.29
-173.6
87.3
Current Ratio 2.55
ALR's Current Ratio is ranked higher than
52% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.43 vs. ALR: 2.55 )
Ranked among companies with meaningful Current Ratio only.
ALR' s Current Ratio Range Over the Past 10 Years
Min: 0.7  Med: 1.78 Max: 3.42
Current: 2.55
0.7
3.42
Quick Ratio 1.96
ALR's Quick Ratio is ranked lower than
54% of the 206 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. ALR: 1.96 )
Ranked among companies with meaningful Quick Ratio only.
ALR' s Quick Ratio Range Over the Past 10 Years
Min: 0.46  Med: 1.35 Max: 2.89
Current: 1.96
0.46
2.89
Days Inventory 95.96
ALR's Days Inventory is ranked lower than
53% of the 165 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 88.85 vs. ALR: 95.96 )
Ranked among companies with meaningful Days Inventory only.
ALR' s Days Inventory Range Over the Past 10 Years
Min: 80.21  Med: 85.99 Max: 97.53
Current: 95.96
80.21
97.53
Days Sales Outstanding 64.56
ALR's Days Sales Outstanding is ranked lower than
51% of the 160 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 64.52 vs. ALR: 64.56 )
Ranked among companies with meaningful Days Sales Outstanding only.
ALR' s Days Sales Outstanding Range Over the Past 10 Years
Min: 60.28  Med: 66.69 Max: 72.77
Current: 64.56
60.28
72.77
Days Payable 52.94
ALR's Days Payable is ranked lower than
55% of the 149 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 60.15 vs. ALR: 52.94 )
Ranked among companies with meaningful Days Payable only.
ALR' s Days Payable Range Over the Past 10 Years
Min: 44.62  Med: 49.74 Max: 59
Current: 52.94
44.62
59

Buy Back

vs
industry
vs
history
Yield on cost (5-Year) 0.50
ALR's Yield on cost (5-Year) is ranked lower than
84% of the 95 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.60 vs. ALR: 0.50 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
ALR' s Yield on cost (5-Year) Range Over the Past 10 Years
Min: 0  Med: 0 Max: 0
Current: 0.5
3-Year Average Share Buyback Ratio -1.60
ALR's 3-Year Average Share Buyback Ratio is ranked higher than
66% of the 129 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -5.80 vs. ALR: -1.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
ALR' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -60.8  Med: -13 Max: 19.3
Current: -1.6
-60.8
19.3

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 1.31
ALR's Price/Projected FCF is ranked higher than
77% of the 69 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.04 vs. ALR: 1.31 )
Ranked among companies with meaningful Price/Projected FCF only.
ALR' s Price/Projected FCF Range Over the Past 10 Years
Min: 0.44  Med: 1.13 Max: 6.47
Current: 1.31
0.44
6.47
Price/Median PS Value 1.08
ALR's Price/Median PS Value is ranked lower than
53% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.05 vs. ALR: 1.08 )
Ranked among companies with meaningful Price/Median PS Value only.
ALR' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.36  Med: 0.94 Max: 2.82
Current: 1.08
0.36
2.82
Earnings Yield (Greenblatt) (%) 0.70
ALR's Earnings Yield (Greenblatt) (%) is ranked higher than
56% of the 205 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -1.00 vs. ALR: 0.70 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ALR' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.6 Max: 3.2
Current: 0.7
0.1
3.2

More Statistics

Revenue (TTM) (Mil) $2,415
EPS (TTM) $ -1.04
Beta-0.40
Short Percentage of Float3.12%
52-Week Range $31.47 - 54.13
Shares Outstanding (Mil)86.74

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 2,477 2,509 2,722
EPS ($) 2.47 2.44 3.17
EPS w/o NRI ($) 2.47 2.44 3.17
EPS Growth Rate
(3Y to 5Y Estimate)
6.71%
Dividends Per Share ($) 0.25 0.25
» More Articles for NYSE:ALR

Headlines

Articles On GuruFocus.com
Opinions Differ on Abbott Deal to Acquire St. Jude's Medical Jun 18 2016 
Keeley Small Cap Value Fund 1st Quarter Commentary Apr 26 2016 
The Transformation in Alere May 22 2015 
Diamond Hill Capital Comments on Alere Inc Mar 17 2015 
Corsair Capital's Analysis of Alere Mar 06 2015 
DENTSPLY´s Growth Opportunities Dec 16 2014 
Hologic Produces the First FDA-Approved 3D Mammography Platform Nov 26 2014 
Mario Gabelli Comments on Alere Inc Nov 21 2014 
Mario Gabelli’s Asset Fund Q3 2014 Commentary Nov 21 2014 
Cohen Has Busy Third Quarter Nov 19 2014 

More From Other Websites
Mediation Talks Between Abbott and Alere Collapse Sep 28 2016
Screening company, 235 jobs jump state line to south KC Sep 22 2016
Abbott Laboratories -- Moody's expectations for Abbott's ratings unchanged following news of medical... Sep 19 2016
Abbott's Eye Deal Isn't About Alere Sep 19 2016
J&J (JNJ) to Buy Abbott's Vision Care Unit for $4.3 Billion Sep 19 2016
Pharos Capital Acquires TechLab, Leading Developer of Gastrointestinal Disease Diagnostics Sep 19 2016
Alro to start a Project co-funded by the Regional Development European Fund Sep 19 2016
[$$] J&J to Buy Abbott’s Eye-Surgery Equipment Unit for $4.325 billion Sep 16 2016
[$$] J&J to Buy Abbott's Eye-Surgery Unit for $4.325 billion Sep 16 2016
Abbott to sell its eye care business to J&J for about $4.33 bln Sep 16 2016
Johnson & Johnson Sees Growth in Ophthalmology, Acquires Abbott Medical Optics Sep 16 2016
Expiry of the validity of the basic Alior Bank SA bonds issuance prospectus Sep 16 2016
Current report in compliance with Regulation no. 1/2006 of NSC and with the stipulations of article... Sep 15 2016
Current report as per art.113 item A letter j) of the National Securities Commission’s Regulation... Sep 15 2016
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock Sep 14 2016
Alere Inc. Declares Cash Dividend on its Series B Convertible Perpetual Preferred Stock Sep 14 2016
Can Abbott Labs Find a Cure for Its Ailing Shares? Sep 12 2016
ALERE INC. Financials Sep 09 2016
Abbott, Alere agree to mediate merger dispute Sep 08 2016
Abbott, Alere agree to mediate merger dispute Sep 08 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)